Literature DB >> 20332120

CCM1 regulates vascular-lumen organization by inducing endothelial polarity.

Maria Grazia Lampugnani1, Fabrizio Orsenigo, Noemi Rudini, Luigi Maddaluno, Gwénola Boulday, Francoise Chapon, Elisabetta Dejana.   

Abstract

Little is known about the molecular mechanisms that regulate the organization of vascular lumen. In this paper we show that lumen formation correlates with endothelial polarization. Adherens junctions (AJs) and VE-cadherin (VEC, encoded by CDH5) are required for endothelial apicobasal polarity in vitro and during embryonic development. Silencing of CDH5 gene expression leads to abrogation of endothelial polarity accompanied by strong alterations in lumenal structure. VEC co-distributes with members of the Par polarity complex (Par3 and PKCzeta) and is needed for activation of PKCzeta. CCM1 is encoded by the CCM1 gene, which is mutated in 60% of patients affected by cerebral cavernous malformation (CCM). The protein interacts with VEC and directs AJ organization and AJ association with the polarity complex, both in cell-culture models and in human CCM1 lesions. Both VEC and CCM1 control Rap1 concentration at cell-cell junctions. We propose that VEC, CCM1 and Rap1 form a signaling complex. In the absence of any of these proteins, AJs are dismantled, cell polarity is lost and vascular lumenal structure is severely altered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332120     DOI: 10.1242/jcs.059329

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  87 in total

1.  Evolution of the VEGF-regulated vascular network from a neural guidance system.

Authors:  Sreenivasan Ponnambalam; Mario Alberghina
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

Review 2.  Vascular lumen formation.

Authors:  Eckhard Lammert; Jennifer Axnick
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 3.  Molecular mechanisms controlling vascular lumen formation in three-dimensional extracellular matrices.

Authors:  Anastasia Sacharidou; Amber N Stratman; George E Davis
Journal:  Cells Tissues Organs       Date:  2011-10-13       Impact factor: 2.481

Review 4.  Formation of cardiovascular tubes in invertebrates and vertebrates.

Authors:  Boris Strilić; Tomás Kucera; Eckhard Lammert
Journal:  Cell Mol Life Sci       Date:  2010-05-20       Impact factor: 9.261

Review 5.  Cellular and molecular mechanisms underlying blood vessel lumen formation.

Authors:  Marta S Charpentier; Frank L Conlon
Journal:  Bioessays       Date:  2013-12-09       Impact factor: 4.345

6.  The structure of Rap1 in complex with RIAM reveals specificity determinants and recruitment mechanism.

Authors:  Hao Zhang; Yu-Chung Chang; Mark L Brennan; Jinhua Wu
Journal:  J Mol Cell Biol       Date:  2013-11-28       Impact factor: 6.216

7.  PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk.

Authors:  Svetlana M Stamatovic; Nikola Sladojevic; Richard F Keep; Anuska V Andjelkovic
Journal:  Acta Neuropathol       Date:  2015-09-18       Impact factor: 17.088

Review 8.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

Review 9.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling.

Authors:  Bryan T Richardson; Christopher F Dibble; Asya L Borikova; Gary L Johnson
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

10.  Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.

Authors:  Lillian Cruz-Orengo; Brian P Daniels; Denise Dorsey; Sarah Alison Basak; José G Grajales-Reyes; Erin E McCandless; Laura Piccio; Robert E Schmidt; Anne H Cross; Seth D Crosby; Robyn S Klein
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.